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Background: Sample size has increasingly become a prerequisite for grant approval. Study size calculations for
multicentre trials are more complicated because these sites present different assumptions on incidence of disease
expected in the control group; this then changes the mechanism of sample size determination. This paper
suggested an alternative approach to estimating study size in multicentre vaccine efficacy trials.
Methods: The approach suggested in this paper was to determine the expected number of events for a given
sample size under set of different assumptions. The power was then calculated given the expected number of
events under the set of assumptions so as to assess the sensitivity of the sample size. The approach was then
illustrated assuming a malaria vaccine efficacy trial planned in four centres.
Results: The approach showed that by assuming 30% cumulative incidence of malaria in three of the centres and
10% cumulative incidence in the other centre, a sample size of 460 children in each centre (total 1,840)
corresponding to a total of 339 events gives 90% power to detect vaccine efficacy of 30% at 5% level of
significance, allowing for 15% loss to follow-up. However, if the incidence is lower than anticipated or a centre
drops out altogether the power will be low. But this would not have much effect if it were a low incidence centre.
Rather, it might have major effect if it were a high incidence centre.
Discussion: Decision on recruitment depends on whether separate estimates of efficacy in each transmission level
are reasonable. If not, equal numbers can be recruited, which then gives safety data for each site and overall
efficacy. Recruiting all or most subjects in the highest transmission site can minimize sample size but may be better
to spread the risk due to uncertainty about incidence due to year to year variation and also the possibility of a site
dropping due to political or other unforeseen problems.
Conclusion: The approach demonstrated the potential of estimating the expected number of events required to
give a specified power for multicentre efficacy trails of blood stage malaria antigens.Background
Planning vaccine efficacy trials requires a major decision
on the number of subjects to enrol on the study in order
to give reasonable statistical power to detect a true effect.
Several approaches – confidence interval and power –
exist for calculating sample size depending on the aim of
the study. If the aim is to obtain estimate of an interven-
tion with a specified level of precision then one can
specify the desired width of the confidence interval and
work out the sample size that achieves that objective. The
power approach aims to estimate a sample size to achieveCorrespondence: sbosomprah@ug.edu.gh
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reproduction in any medium, provided the ora specified power and this is the approach emphasized in
this paper. The basic principle is to quantify the primary
objective of the study in terms of certain statistical para-
meters. Specifically, the statistical considerations are to
state a null hypothesis with its associated type I error rate
and an alternative hypothesis with its associated statistical
power; also, the test statistic that distinguished between
the two hypotheses [1,2]. Having specified these para-
meters, an exercise is then performed to determine the
number of participants required to achieve the stated type
I error rate and the power simultaneously. For test statistic
that has standard distributional properties, one can easily
apply the standard formula to estimate the sample size.
However, controlled trials often deviate from standard
assumptions so that the test statistic becomes moretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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proach the sample size estimation in three ways. First, one
can use the standard formula to approximate the study
size over a possible range of parameters given a set of ideal
assumptions, such as no loss to follow-up, independence
of events, full compliance, among others. This gives an
idea about the resources needed in the study. Second, ha-
ving identified the likely deviation from the assumption,
one can adjust the study size accordingly. Finally, if the
trial includes highly specialized features, one can consider
simulation to select a more appropriate study size [3,4].
The exercise of sample size calculation can be iterative.
For instance, one can extend the follow-up time to reduce
the sample size. One can also change the inclusion criteria
to increase event rates. One can even select study sites
that have a good history of retention in order to reduce
loss to follow-up. This systematic approach is aimed at
producing a reasonable sample size for the study because
a sample size too small can lead to low statistical power,
whereas too large a sample can be a waste of time and
resources and can also be unethical.
In trials with binary outcomes or time to event out-
comes, the word “small” refers not to the number of
patients studied but rather to the number of events ob-
served. For instance, a trial of 3,000 children on placebo
and 3,000 on a new vaccine being followed for 12 months
to study the effect of the new vaccine in preventing cli-
nical malaria can be considered as “small” in the termi-
nology of controlled trials, if it suggests that only about 20
events are expected to occur in the control group. The
99% or so of children who do not experience clinical mal-
aria provide essentially no information about the effect of
the vaccine. Therefore, an alternative approach that esti-
mates the expected number of events in the control group
required to give a specified power forms part of this paper.
The sample size in a controlled trial cannot be arbitrarily
large. The total number of participants potentially avai-
lable, the budget, and the amount of time available can in-
fluence the number of participants to be included in a
trial. The sample size of a trial must be adequate to allow
a reasonable chance of answering the research question
but not so large that continuing randomization will lead
to ethical discomfort. Where a larger number of partici-
pants are anticipated in different epidemiological settings
with a wider range of population groups, one strategy is to
carry out the study in more than one centre - multicentre
design. This is particularly useful where the number of po-
tential participants available in a study centre is limited. It
ensures the ability to compare results among centres and
increases the generalizability of the results. Such trials
have been conducted during the past decade [5,6]. The de-
sign and analysis of these trials are not straightforward
compared with single-centre trials. This is because these
centres present different assumptions on incidence ofdisease expected in the control group, which then changes
the mechanism of sample size determination. In vaccine
trials, the primary objective is often to compare incidence
rate or hazard rate of some disease, say, malaria in the
intervention group with that in the control group and so
this paper focused on comparison of incidence rates in
two groups.
Methods
Donner reviewed approaches to sample size estimation
in the design of clinical trials [7]. Sample size formulae
depend on the type of primary outcome being investi-
gated in the study and are guided by both statistical and
resource considerations.
Smith and Morrow [2] showed that for single-centre
trial, the person-years at risk, y, of observation in each
group is given by:
y ¼ zα=2 þ zβ
 2
λc þ λvð Þ
λc−λvð Þ2
ð1Þ
Where zα/2 is the percentage of the standard normal
distribution corresponding to the required two-sided
significant level (for example, if significance level =5%,
zα/2 =1.96); zβ is one-sided percentage point of the
standard normal distribution corresponding to 100% - the
power (for example, if power = 90%, (100% - power) =10%
and zβ =1.28); λc is the incidence rate in the control group
and λv is the incidence rate in the vaccine group. By defi-
nition, rate is the number of new cases divided by total
person-time at risk. Therefore, the number of events in
each group is given by the product of rate, λ, and person-
time at risk, y. So, if it is assumed that the person-years at
risk is the same in both group the total expected number
of events, E(n), is given by:
E nð Þ ¼ λc þ λvð Þy ð2Þ
the sample size necessary to expect E(n) events can be
derived from equations (1) and (2) using:
N ¼ y  2þ E nð Þ M ð3Þ
where E(n)*M is the adjustment factor for risk-free period
after anti-malarial treatment. That is, M is the number of
weeks the child is assumed not at risk, expressed in year,
after each treatment. For example, if it is assumed that the
child is not at risk for three weeks after anti-malarial treat-
ment then M=3/52.
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be derived from the cumulative incidence, r:
Risk up to time; t ¼ r ¼ 1−e−λt ð4Þ
Re-arranging eqn (4) gives
λc ¼ −ln 1−rð Þ=t ð5Þ
For multicentre trials the formula becomes more
complicated because one needs to work out the expected
number of events in each centre, assuming a specified
sample size, to give a reasonable power. The total ex-
pected number of events, E(n), in terms of the relative
rate, θ, and the sample size, N, for an expected incidenceTable 1 Sample size in each site to give the required expecte
eqn (6)
Centres % malaria after six
months
Sample size (all the required number
can be recruited)




























Total 1,380rate in the control group, λc, assuming a fraction loss to
follow up, L, is given by:
E nð Þ ¼ λc þ 1− exp − − ln 1−λcð Þθð Þð Þ½ N2  1−Lð Þ ð6Þ
The power for a given expected number of events re-
quired in the control group, Ec(=E(n)/1 + θ), for a spe-
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cumulative distribution of zβd number of events under different scenarios using
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Assume a sample size requirement for a malaria vaccine
efficacy trial planned in four centres: A, B, C and D. The
primary objective of the trial was to assess the efficacy of
a candidate vaccine against Plasmodium falciparum cli-
nical malaria episodes in children aged 12–60 months at
first vaccination over a six-month surveillance period,
starting from the day of the third dose of vaccination. It
was proposed that the primary analysis would be done
as soon after six months of follow-up had elapsed if at
least 330 children had had an episode of malaria. In case
the target number is not reached by 12 months, analysis
will be carried out at 12 months. Table 1 shows the sam-
ple size corresponding to total expected number of
events under different scenarios. If 30% cumulative inci-
dence of malaria in three of the centres (B, C, and D)
and 10% cumulative incidence in centre A is assumed,
then a sample size of 460 children in each centre (total
1,840) corresponding to a total of 339 events gives 90%
power to detect vaccine efficacy of 30% at 5% level of
significance, allowing for 15% loss to follow-up (Tables 1
and 2 - Scenario 1). If the incidence is lower than antici-
pated or a centre drops out altogether the power will be
low. But this would not have much effect if it were a low
incidence centre. Rather, it might have major effect if it
were a high incidence centre. If incidence in centre A is
very low, say 5%, rather than the 10% assumed as in
Scenario 2, the power will be 89% to detect vaccine effi-
cacy of 30%. If incidence is very low in both centres, A
and B, say 5% as in Scenario 3, the power will be 78% to
detect vaccine efficacy of 30%. If all the sites have inci-
dence reduced to half, the power will be 63% to detect
vaccine efficacy of 30%. If centre D drops out altogether
the power will be 78% to detect vaccine efficacy of 30%. If
the sample size is lower than anticipated due to, say,
resource constraint, the expected number of events will
be lower and the power will be less. If only 70% of the
sample size anticipated can be recruited under the sameTable 2 The power for expected number of events required in
different scenarios as in Table 1 using eqn (7)
Scenarios Sample size E(n) Alpha
Scenario 1 1,840 339 0.05
1,288 237 0.05
Scenario 2 1,840 322 0.05
1,288 226 0.05
Scenario 3 1,840 237 0.05
1,288 166 0.05
Scenario 4 1,840 168 0.05
1,288 117 0.05
Scenario 5 1,380 237 0.05
966 166 0.05assumption of incidence as in Scenario 1, the expected
number of events will be reduced from 339 to 237 and the
power will be 78% to detect vaccine efficacy of 30%.
Discussion
Sample size has increasingly become a prerequisite for
grant approval. This paper suggested an alternative ap-
proach to estimating study size in multicentre vaccine effi-
cacy trials. Study size calculations for multicentre trials
are more complicated because these sites present different
assumptions on incidence of disease expected in the con-
trol group; this then changes the mechanism of sample
size determination. The approach suggested in this paper
is to determine the expected number of events for a given
sample size under set of different assumptions. The power
is then calculated given the expected number of events
under the set of assumptions so as to assess the sensitivity
of the sample size. Even though investigators often spend
much time on the number of participants to enrol on trial,
the sample size is not the only factor that influences the
power of a trial. The total number of primary outcome
experienced by the population is a critical factor because a
large sample size with low event rate in the population
can lead to low power. Therefore, in designing a trial it is
important to consider how the estimated number of pri-
mary outcome can be realised. One strategy to ensure
enough number of events is to select a high-risk group for
the trial. The age of participants might help in identifying
this group. Although oversampling a high-risk group
might give more cases, it may make it more difficult to
generalize the results to the general population. Another
strategy is to extend the duration of follow-up, but this
might not be useful in areas of low transmission. It may
be decided to evaluate vaccines in low transmission set-
tings but the sample size would need to be very high. It
may not be possible to power the study to be able to test
for interactions. Increasingly, it may be difficult to mea-
sure efficacy against severe disease due to low incidence.the control group for a specific relative rate, θ, for the
zα/2 θ Ec zβ Power
1.96 0.7 199.412 1.2892 0.90
1.96 0.7 139.412 0.75677 0.78
1.96 0.7 189.412 1.20669 0.89
1.96 0.7 132.941 0.69297 0.76
1.96 0.7 139.412 0.75677 0.78
1.96 0.7 97.6471 0.3137 0.62
1.96 0.7 98.8235 0.32736 0.63
1.96 0.7 68.8235 −0.05114 0.48
1.96 0.7 139.412 0.75677 0.78
1.96 0.7 97.6471 0.3137 0.62
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different transmission levels, and need to have optimum
power for given sample size. Decision depends on whether
separate estimates of efficacy in each transmission level
are reasonable. If not, equal numbers can be recruited,
which then gives safety data for each site and overall effi-
cacy. Recruiting all or most subjects in the highest trans-
mission site can minimize sample size but may be better
to spread the risk due to uncertainty about incidence due
to year-to-year variation, and also the possibility of a site
dropping due to political or other unforeseen problems.
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